Treatment Modalities in Hypertrophic Obstructive Cardiomyopathy: Surgical Myectomy versus Percutaneous Septal Ablation
DOI:
https://doi.org/10.1532/HSF98.20071136Abstract
Background. The aim of this study was to compare the results of percutaneous septal myocardial ablation (PSMA) and surgical myectomy (SM) for decreasing the left ventricular outflow tract (LVOT) gradient, septal thickness, ventricular dimensions, and mitral regurgitation (MR) in patients with symptomatic hypertrophic obstructive cardiomyopathy.
Methods: We treated 40 patients (mean age, 24.4 ± 6.8 years; 34 male and 6 female patients) between June 2002 and April 2006. Twenty-four patients underwent SM, and 16 patients underwent PSMA. All patients were symptomatic despite maximal medical treatment and had an LVOT gradient higher than 65 mm Hg. Their echocardiographic data were recorded before and after the procedure and then compared. The patients were followed up postoperatively for a mean of 13 months.
Results: There was no mortality in either group. One year after the procedure, the LVOT gradients for the 2 groups were not statistically different. During the follow-up, moderate MR was found in 4 patients (25%) in the ablation group and in 2 patients (8.3%) in the myectomy group. Exercise capacity and New York Heart Association class improved after PSMA, whereas postoperative MR severity and effort capacity were better in the surgical group.
Conclusion: The 2 approaches yielded similar results with regard to reducing the LVOT gradient. We conclude that SM is preferable to PSMA in cases with MR.
References
Cooley DA. 1991. Surgical techniques for hypertrophic left ventricular obstructive myopathy including mitral valve plication. J Card Surg 6:29-33.nFerrari R, Rydén L. 2001. Hypertrophic cardiomyopathy: from molecular and genetic mechanisms to clinical management. Eur Heart J Suppl 3(Suppl L):L1-2.nGietzen FH, Leuner CJ, Raute-Kreinsen U, et al. 1999. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH): catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 20:1342-54.nIvens E. 2004. Hypertrophic cardiomyopathy. Heart Lung Circ 13(Suppl 3):S48-55.nLakkis NM, Nagueh SF, Dunn JK, Killip D, Spencer WH 3rd. 2000. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up. J Am Coll Cardiol 36:852-5.nLever HM. 2006. Selection of hypertrophic cardiomyopathy patients for myectomy or alcohol septal ablation. Anadolu Kardiyol Derg 6(Suppl 2):27-30.nMaron BJ. 2002. Hypertrophic cardiomyopathy: a systematic review. JAMA 287:1308-20.nMarwick TH, Stewart WJ, Lever HM, et al. 1992. Benefits of intraoperative echocardiography in the surgical management of hypertrophic cardiomyopathy. J Am Coll Cardiol 20:1066-72.nMcIntosh CI, Maron BJ, Cannon RO, Klues HG. 1992. Initial results of combined anterior mitral leaflet plication and ventricular septal myotomy-myectomy for relief of left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. Circulation 86(Suppl 2):60-7.nMorrow AG, Reitz BA, Epstein SE, et al. 1975. Operative treatment in hypertrophic subaortic stenosis: techniques, and the results of pre and postoperative assessments in 83 patients. Circulation 52:88-102.nRalph-Edwards A, Woo A, McCrindle BW, et al. 2005. Hypertrophic obstructive cardiomyopathy: comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score. J Thorac Cardiovasc Surg 129:351-8.nRoberts R, Sigwart U. 2005. Current concepts of the pathogenesis and treatment of hypertrophic cardiomyopathy. Circulation 112:293-6.nSchoendube FA, Klues HG, Reith S, Flachskampf FA, Hanrath P, Messmer BJ. 1995. Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus. Circulation 92(9 Suppl):II122-7.nSeggewiss H, Faber L, Gleichmann U. 1999. Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy. Thorac Cardiovasc Surg 47:94-100.nSigwart U. 2001. Non-surgical myocardial reduction for patients with hypertrophic obstructive cardiomyopathy. Eur Heart J Suppl 3(Suppl L):L38-42.nSitges M, Shiota T, Lever HM, et al. 2003. Comparison of left ventricular diastolic function in obstructive hypertrophic cardiomyopathy in patients undergoing percutaneous septal alcohol ablation versus surgical myotomy/myectomy. Am J Cardiol 91:817-21.nSpirito P, Seidman CE, McKenna WJ, Maron BJ. 1997. The management of hypertrophic cardiomyopathy. N Engl J Med 336:775-85.nTalreja DR, Nishimura RA, Edwards WD, et al. 2004. Alcohol septal ablation versus surgical septal myectomy: comparison of effects on atrioventricular conduction tissue. J Am Coll Cardiol 44:2329-32.nvan der Lee C, ten Cate FJ, Geleijnse ML, et al. 2005. Percutaneous versus surgical treatment for patients with hypertrophic obstructive cardiomyopathy and enlarged anterior mitral valve leaflets. Circulation 112:482-8.nWigle ED, Rakowski H, Kimball B, Wiliams WG. 1995. Hypertrophic cardiomyopathy: clinical spectrum and treatment. Circulation 92:1680-92.nWigle ED, Sasson Z, Henderson MA, et al. 1985. Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy: a review. Prog Cardiovasc Dis 28:1-83.nYacoub MH. 2005. Surgical versus alcohol septal ablation for hypertrophic obstructive cardiomyopathy: the pendulum swings. Circulation 112:450-2.nYoerger DM, Weyman AE. 2003. Hypertrophic obstructive cardiomyopathy: mechanism of obstruction and response to therapy. Rev Cardiovasc Med 4:199-215.nZhu YB, Rajan S, Kurian VM, Liu ZY. 2006. Surgical outcomes and strategy of hypertrophic obstructive cardiomyopathy. J Zhejiang Univ Sci B 7:148-53.n
